Cargando…
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
A DNA vaccine, SCIB1, incorporating two CD8 and two CD4 epitopes from TRP-2/gp100 was evaluated in patients with metastatic melanoma. Each patient received SCIB1 via intramuscular injection with electroporation. The trial was designed to find the safest dose of SCIB1 which induced immune/clinical re...
Autores principales: | Patel, Poulam M., Ottensmeier, Christian H., Mulatero, Clive, Lorigan, Paul, Plummer, Ruth, Pandha, Hardev, Elsheikh, Somaia, Hadjimichael, Efthymios, Villasanti, Naty, Adams, Sally E., Cunnell, Michelle, Metheringham, Rachael L., Brentville, Victoria A., Machado, Lee, Daniels, Ian, Gijon, Mohamed, Hannaman, Drew, Durrant, Lindy G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980353/ https://www.ncbi.nlm.nih.gov/pubmed/29872563 http://dx.doi.org/10.1080/2162402X.2018.1433516 |
Ejemplares similares
-
Citrullinated α-enolase is an effective target for anti-cancer immunity
por: Cook, Katherine, et al.
Publicado: (2017) -
High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
por: Brentville, Victoria A., et al.
Publicado: (2012) -
PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022) -
Citrullinated Epitopes Identified on Tumour MHC Class II by Peptide Elution Stimulate Both Regulatory and Th1 Responses and Require Careful Selection for Optimal Anti-Tumour Responses
por: Symonds, Peter, et al.
Publicado: (2021) -
T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy
por: Brentville, Victoria A, et al.
Publicado: (2019)